All In Biotech

Drug Trial Radar · NCT05276726

A Study of JAB-21822 in Advanced or Metastatic NSCLC With KRAS p.G12C and STK11 Co-mutation and Wild-type KEAP1

A Phase Ib/II ,Single Arm, Multi-Center, Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of JAB-21822 in Advanced or Metastatic Non-small Cell Lung Cancer With a KRAS p.G12C and STK11 Co-mutation and Wild-type KEAP1

Last checked: Nov 20, 2026Latest source record: Aug 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

104

Planned (sponsor's estimate)

Start

Aug 17, 2022

Primary completion

Aug 2027

Study completion Aug 2027

Sponsor

Lead sponsor
Allist Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
Mar 11, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Evaluate the safety and tolerability, drug levels, and clinical activity of JAB-21822 in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors with KRAS p.G12C mutation and a serine/threonine kinase 11 (STK11) co-mutation.

Conditions

  • Non-small Cell Lung Cancer

Interventions

  • JAB 21822Drug

    Administered orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose Escalation phase Number of participants with dose limiting toxicities (DLTs)Time frame: At the end of Cycle 1 (each cycle is 21 days)
  2. Dose Escalation phase: Number of participants with adverse eventsTime frame: Up to 3 years
  3. Dose Expansion phase: Objective response rate (ORR)Time frame: Up to 3 years - from baseline to confirmed Progressive Disease per RECIST.

Locations

21 sites in 1 country. Site status is shown where the registry gives one.

  • Research site08

    Beijing, Beijing Municipality, China · Not yet recruiting

  • Research site09

    Beijing, Beijing Municipality, China · Not yet recruiting

  • Research site021

    Beijing, Beijing Municipality, China · Not yet recruiting

  • Research site02

    Beijing, Beijing Municipality, China · Not yet recruiting

  • Research site01

    Beijing, Beijing Municipality, China · Recruiting

  • Research site013

    Beijing, Beijing Municipality, China · Not yet recruiting

  • Research site010

    Chongqing, Chongqing Municipality, China · Not yet recruiting

  • Research site05

    Xiamen, Fujian, China · Not yet recruiting

  • Research site011

    Shenzhen, Guangdong, China · Not yet recruiting

  • Research site016

    Nanning, Guangxi, China · Not yet recruiting

  • Research site017

    Shijiazhuang, Hebei, China · Not yet recruiting

  • Research site018

    Harbin, Heilongjiang, China · Not yet recruiting

  • Research site04

    Zhengzhou, Henan, China · Not yet recruiting

  • Research site012

    Changsha, Hunan, China · Not yet recruiting

  • Research site015

    Changchun, Jilin, China · Not yet recruiting

  • Research site06

    Shenyang, Liaoning, China · Not yet recruiting

  • Research site07

    Shenyang, Liaoning, China · Not yet recruiting

  • Research site014

    Hohhot, Neimenggu, China · Not yet recruiting

  • Research site020

    Xi’an, Shanxi, China · Not yet recruiting

  • Research site03

    Hubei, Wuhan, China · Not yet recruiting

  • Research site019

    Hangzhou, Zhejiang, China · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.